Toward Greater Transparency at the FDA—Now Is the Time to Act
JAMA · 14.04.2026 · 335 (14) · 1203
DOI: 10.1001/jama.2026.1652 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 14.04.2026. Verfasst von Irene Park Ulrich und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Science in the Public Interest, Washington, DC. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint considers the US Food and Drug Administration’s track record for transparency and urges the agency to fortify transparency efforts.
Autor:innen und Institutionen
- Center for Science in the Public Interest, Washington, DC.
Zitieren
APA
Ulrich, I. P., & Lurie, P. G. (2026). Toward Greater Transparency at the FDA—Now Is the Time to Act. JAMA, 335(14), 1203. https://doi.org/10.1001/jama.2026.1652
Vancouver
Ulrich IP, Lurie PG. Toward Greater Transparency at the FDA—Now Is the Time to Act. JAMA. 2026;335(14):1203. doi:10.1001/jama.2026.1652
BibTeX
@article{Ulrich2026,
author = {Ulrich, Irene Park and Lurie, Peter G},
title = {Toward Greater Transparency at the FDA—Now Is the Time to Act},
journal = {JAMA},
year = {2026},
volume = {335},
number = {14},
pages = {1203},
doi = {10.1001/jama.2026.1652}
}
EUVIMED